

Supplemental references

- S1. Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman, Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science*, 1993. **259**(5091): p. 87-91.
- S2. Hotamisligil, G.S., et al., Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance. *J Clin Invest*, 1995. **95**(5): p. 2409-15.
- S3. Hotamisligil, G.S., et al., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α - and obesity-induced insulin resistance. *Science*, 1996. **271**(5249): p. 665-8.
- S4. Uysal, K.T., et al., Protection from obesity-induced insulin resistance in mice lacking TNF- α function. *Nature*, 1997. **389**(6651): p. 610-4.
- S5. Xu, H., et al., Exclusive action of transmembrane TNF α in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. *Endocrinology*, 2002. **143**(4): p. 1502-11.
- S6. Vozarova, B., et al., Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. *Obes Res*, 2001. **9**(7): p. 414-7.
- S7. Bastard, J.P., et al., Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. *J Clin Endocrinol Metab*, 2002. **87**(5): p. 2084-9.
- S8. Senn, J.J., et al., Interleukin-6 induces cellular insulin resistance in hepatocytes. *Diabetes*, 2002. **51**(12): p. 3391-9.
- S9. Rotter, V., I. Nagaev, and U. Smith, Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor- α , overexpressed in human fat cells from insulin-resistant subjects. *J Biol Chem*, 2003. **278**(46): p. 45777-84.
- S10. Wallenius, V., et al., *Interleukin-6-deficient mice develop mature-onset obesity*. *Nat Med*, 2002. **8**(1): p. 75-9.
- S11. Klover, P.J., et al., Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. *Diabetes*, 2003. **52**(11): p. 2784-9.
- S12. Friedman, J.M. and J.L. Halaas, *Leptin and the regulation of body weight*

in mammals. Nature, 1998. **395**(6704): p. 763-70.

S13. La Cava, A. and G. Matarese, *The weight of leptin in immunity*. Nat Rev Immunol, 2004. **4**(5): p. 371-9.

S14. Minokoshi, Y., et al., Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature, 2002. **415**(6869): p. 339-43.

S15. Berg, A.H., T.P. Combs, and P.E. Scherer, *ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism*. Trends Endocrinol Metab, 2002. **13**(2): p. 84-9.

S16. Ouchi, N., et al., *Obesity, adiponectin and vascular inflammatory disease*. Curr Opin Lipidol, 2003. **14**(6): p. 561-6.

S17. Kubota, N., et al., Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem, 2002. **277**(29): p. 25863-6.

S18. Yamauchi, T., et al., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipotrophy and obesity. Nat Med, 2001. **7**(8): p. 941-6.

S19. Combs, T.P., et al., A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology, 2004. **145**(1): p. 367-83.

S20. Fukuhara, A., et al., Visfatin: A Protein Secreted by Visceral Fat that Mimics the Effects of Insulin. Science, 2004.

S21. Samal, B., et al., Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol, 1994. **14**(2): p. 1431-7.

S22. Stepan, C.M. and M.A. Lazar, *The current biology of resistin*. J Intern Med, 2004. **255**(4): p. 439-47.

S23. Lehrke, M., et al., An Inflammatory Cascade Leading to Hyperresistinemia in Humans. Plos Med, 2004. **1**(2): p. e45.

S24. Banerjee, R.R., et al., *Regulation of fasted blood glucose by resistin*. Science, 2004. **303**(5661): p. 1195-8.

S25. Muse, E.D., et al., *Role of resistin in diet-induced hepatic insulin resistance*. J Clin Invest, 2004. **114**(2): p. 232-9.

S26. Stepan, C.M., et al., *The hormone resistin links obesity to diabetes*. Nature, 2001. **409**(6818): p. 307-12.

- S27. Satoh, H., et al., Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. *J Clin Invest*, 2004. **114**(2): p. 224-31.
- S28. Maedler, K., et al., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. *J Clin Invest*, 2002. **110**(6): p. 851-60.
- S29. Luheshi, G.N., et al., *Leptin actions on food intake and body temperature are mediated by IL-1*. *Proc Natl Acad Sci U S A*, 1999. **96**(12): p. 7047-52.
- S30. Matsuki, T., et al., IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. *J Exp Med*, 2003. **198**(6): p. 877-88.
- S31. Juge-Aubry, C.E., et al., Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. *Diabetes*, 2003. **52**(5): p. 1104-10.
- S32. Strackowski, M., et al., Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. *J Clin Endocrinol Metab*, 2002. **87**(10): p. 4602-6.
- S33. Boisvert, W.A., et al., A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. *J Clin Invest*, 1998. **101**(2): p. 353-63.
- S34. Gerszten, R.E., et al., MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. *Nature*, 1999. **398**(6729): p. 718-23.
- S35. Esposito, K., et al., Association of low interleukin-10 levels with the metabolic syndrome in obese women. *J Clin Endocrinol Metab*, 2003. **88**(3): p. 1055-8.
- S36. Kim, H.J., et al., Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. *Diabetes*, 2004. **53**(4): p. 1060-7.
- S37. Esposito, K., et al., *Weight loss reduces interleukin-18 levels in obese women*. *J Clin Endocrinol Metab*, 2002. **87**(8): p. 3864-6.
- S38. Escobar-Morreale, H.F., et al., Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. *J Clin Endocrinol Metab*, 2004. **89**(2): p. 806-11.
- S39. Whitman, S.C., P. Ravisankar, and A. Daugherty, Interleukin-18 enhances

atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. *Circ Res*, 2002. **90**(2): p. E34-8.

S40. Elhage, R., et al., Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. *Cardiovasc Res*, 2003. **59**(1): p. 234-40.

S41. Sartipy, P. and D.J. Loskutoff, *Monocyte chemoattractant protein 1 in obesity and insulin resistance*. *Proc Natl Acad Sci U S A*, 2003. **100**(12): p. 7265-70.

S42. Boring, L., et al., Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature*, 1998. **394**(6696): p. 894-7.

S43. Skurk, T., et al., Production and release of macrophage migration inhibitory factor from human adipocytes. *Endocrinology*, 2005. **146**(3): p. 1006-11.

S44. Levine, J.A., et al., Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. *J Clin Invest*, 1998. **101**(8): p. 1557-64.

S45. Samad, F., et al., Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. *Mol Med*, 1997. **3**(1): p. 37-48.

S46. Alessi, M.C., et al., Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. *Diabetes*, 2000. **49**(8): p. 1374-80.

S47. Grainger, D.J., Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. *Arterioscler Thromb Vasc Biol*, 2004. **24**(3): p. 399-404.

S48. Ignatz, R.A. and J. Massague, Type beta transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. *Proc Natl Acad Sci U S A*, 1985. **82**(24): p. 8530-4.

S49. Clouthier, D.E., S.A. Comerford, and R.E. Hammer, Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCCK-TGF-beta1 transgenic mice. *J Clin Invest*, 1997. **100**(11): p. 2697-713.

S50. Gojova, A., et al., Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. *Blood*, 2003. **102**(12): p. 4052-8.

S51. Robertson, A.K., et al., Disruption of TGF-beta signaling in T cells

accelerates atherosclerosis. *J Clin Invest*, 2003. **112**(9): p. 1342-50.

S52. Hotamisligil, G.S., et al., Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. *Diabetes*, 1997. **46**(3): p. 451-5.

S53. Fernandez-Real, J.M., et al., Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. *Diabetes*, 1998. **47**(11): p. 1757-62.

S54. Hauner, H., et al., *Plasma concentrations of soluble TNF-alpha receptors in obese subjects*. *Int J Obes Relat Metab Disord*, 1998. **22**(12): p. 1239-43.

S55. Pannacciulli, N., et al., C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. *Int J Obes Relat Metab Disord*, 2001. **25**(10): p. 1416-20.

S56. Aronson, D., et al., Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. *Int J Obes Relat Metab Disord*, 2004. **28**(5): p. 674-9.

S57. Paul, A., et al., C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. *Circulation*, 2004. **109**(5): p. 647-55.

S58. Nakanishi, S., et al., Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. *Diabetes Care*, 2003. **26**(10): p. 2754-7.

S59. Pradhan, A.D., et al., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *Jama*, 2001. **286**(3): p. 327-34.

S60. Chiellini, C., et al., Obesity modulates the expression of haptoglobin in the white adipose tissue via TNFalpha. *J Cell Physiol*, 2002. **190**(2): p. 251-8.